OncoMatch/Clinical Trials/NCT05201404
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Is NCT05201404 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Namodenoson for hepatocellular carcinoma.
Treatment: Namodenoson — This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — HCC
HCC has progressed on at least 1, but no more than 2, prior systemic treatment regimens
Cannot have received: systemic drug therapy
Receipt of >2 prior systemic drug therapies for HCC
Cannot have received: systemic cancer therapy
Exception: within 14 days prior to the Baseline Visit or concurrently during the trial
Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive therapy, or corticosteroids > 20 mg/day prednisone or equivalent within 14 days prior to the Baseline Visit or concurrently during the trial
Cannot have received: locoregional treatment
Exception: within 4 weeks prior to the Baseline Visit
Locoregional treatment within 4 weeks prior to the Baseline Visit
Cannot have received: major surgery or radiation therapy
Exception: within 4 weeks prior to the Baseline Visit
Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit
Cannot have received: investigational agent
Exception: within 4 weeks prior to the Baseline Visit
Use of any investigational agent within 4 weeks prior to the Baseline Visit
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L; Platelet count at least 75 × 10^9/L
Kidney function
Creatinine clearance at least 50 mg/dL (estimated by Cockcroft-Gault or MDRD methods)
Liver function
AST and ALT ≤ 5 × ULN; Total bilirubin ≤ 3.0 mg/dL; Serum albumin ≥ 2.8 g/dL
ANC ≥ 1.5 × 10^9/L; Platelet count at least 75 × 10^9/L; Creatinine clearance at least 50 mg/dL; AST and ALT ≤ 5 × ULN; Total bilirubin ≤ 3.0 mg/dL; Serum albumin ≥ 2.8 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 881 · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05201404 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic drug therapy, systemic cancer therapy, locoregional treatment disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages